## CLAIMS

1. An oral composition comprising ~~a therapeutically effective amount of~~ theobromine and a plurality of additional therapeutic compounds having antitusive activity for reducing a symptom associated with a coughing condition, wherein the plurality of therapeutic compounds having antitusive activity include a decongestant, an expectorant, a mucolytic agent, an anti-histamine, a non-steroidal anti-inflammatory drug (NSAID), a neuropathic pain agent, a terpene, an ACE inhibitor, an angiotensin II receptor antagonist or any combination thereof, and wherein the plurality of therapeutic compounds does not include a non-opiate antitussive agent.

2. The oral composition according to Claim 1, wherein the plurality of therapeutic compounds having antitusive activity includes ~~a non-opiate antitussive agent, an opiate antitussive agent,~~ a decongestant, an expectorant, a mucolytic agent, an anti-histamine~~, a non-steroidal anti-inflammatory drug (NSAID), a neuropathic pain agent~~, a terpene~~, an ACE inhibitor, an angiotensin II receptor antagonist~~ or any combination thereof.

3. The oral composition according to Claim 1 or Claim 2, wherein the plurality of therapeutic compounds having antitusive activity includes a mucolytic agent, an anti-histamine and a terpene.

4. The oral composition according to any one of Claims 1-3, wherein the plurality of therapeutic compounds having antitusive activity includes diphenhydramine, ammonim chloride and l-menthol.

5. The oral composition according to any one of Claims 1-3, wherein the non-opuiate antitussive agent is dextromethorphan.

~~3~~6. The oral composition according to any one of Claims 1-5~~ or Claim 2~~, wherein the antitussive activity suppresses a vagal nerve function associated with a cough, suppresses a central nerve function associated with a cough, and/or suppresses a peripheral nerve function associated with a cough.

47. The oral composition according to any one of Claims 1-~~3~~6, wherein the antitussive activity is not associated with an unwanted side.

58. The oral composition according to Claim 47, wherein the unwanted side includes sedation, cognitive fogging, dizziness, drowsiness, postural hypertension, coordination problems, weakness, tremors, respiratory depression, psychotropic effects, sleep disturbances, unwanted waitfulness, CNS stimulation, weight gain, appetite change, change in sexual function, constipation, dry mouth, gut erosion, gastric ulcerations, renal inflammation, cardiovascular hypertension, cardiovascular stimulation, hyperchlimina, not going into public, chest pain, stress incontinence, or any combination thereof.

~~6. The oral composition according to any one of Claims 1-5, wherein the antitussive activity reduces a symptom associated with a coughing condition.~~

79. The oral composition according to any one of Claims 1-86, wherein the symptom includes the frequency of a cough, the severity of a cough, the volume or noise level of a cough, hoarseness, sore throat, breathing difficulty, respiratory congestion, wheezing, respiratory constriction, respiratory inflammation, muscle spasms associated with a cough, phlegm production, fainting, insomnia, vomiting, subconjunctival hemorrhage (red eye), cough defecation, cough urination, abdominal hernia, pelvic hernia, costochondritis, or lower rib fracture.

~~8~~10. The oral composition according to any one of Claims 1-~~7~~9, wherein the antitussive activity suppresses an acute coughing condition, a subacute coughing condition, a chronic coughing condition, a non-productive coughing condition, a productive coughing condition, or a cough associated with a disease or disorder.

~~9~~11. Use of an oral composition as defined in any one of Claims 1-~~8~~ 10 in the manufacture of a medicament for the treatment of a coughing condition.

~~10~~12. The use according to Claim ~~9~~11, wherein the coughing condition comprises an acute coughing condition, a subacute coughing condition, a chronic coughing condition, a non-productive coughing condition, a productive coughing condition, or a cough associated with a disease or disorder.

~~11~~13. The use according to Claim ~~10~~12, wherein the disease or disorder is an asthma, an atopic cough a bronchitis, a gastroesophageal reflux disease, an infection of the respiratory tract, an inflammation, a medication, a pollutant, a post-nasal drip, a smoking event, a vagal nerve irritation, a diseases of the external auditory canal, a lung disease, a lung tumor, a habit cough, a tic, a Tourette syndrome, a cardiovascular disease, or a post-infectious cough.

~~12~~14. The use according to any one of Claims ~~9~~11-~~11~~13, wherein the treatment reduces a symptom associated with a coughing condition.

~~13~~15. The use according to Claim ~~12~~14, wherein the symptom includes coughing, hoarseness, sore throat, breathing difficulty, respiratory congestion, wheezing, respiratory constriction, respiratory inflammation, muscle spasms associated with a cough, phlegm production, fainting, insomnia, vomiting, subconjunctival hemorrhage, cough defecation, cough urination, abdominal hernia, pelvic hernia, costochondritis, lower rib fracture, or any combination thereof.